Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Prelude Therapeutics
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05107856CT.gov PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | — | Terminated | — | — | — |
NCT04603001CT.gov Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | — | Active Not Recruiting | — | — | — |
NCT04146038CT.gov Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | — | Completed | — | — | — |
NCT04022785CT.gov PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT03862157CT.gov Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Active Not Recruiting | — | — | — |
NCT03588078CT.gov Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine | — | Unknown | — | — | — |
NCT03471260CT.gov Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | — | Recruiting | — | — | — |
NCT03397173CT.gov TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid | — | Completed | — | — | — |
NCT03072043CT.gov Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myeloproliferative Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Azacitidine (this asset) | Prelude Therapeutics | P2 | BB · 66 |
| Melphalan | Center for International Blood and Marrow Transplant Research | P2/3 | BBB |
| Fludarabine | Sawa Ito, MD | P4 | BB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Fred Hutchinson Cancer Center | P2/3 | BB |
| Romidepsin | Sawa Ito, MD | P4 | BB |
| Nivestim | City of Hope Medical Center | P3 | BB |
| Carboplatin | OHSU Knight Cancer Institute | P2/3 | BB |
| Cyclosporin A | City of Hope Medical Center | P3 | BB |
| Busulfanum | Sawa Ito, MD | P4 | BB |
+42 more in the Myeloproliferative Neoplasm cohort
Other indications for Azacitidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 73 |
| Acute Erythroid Leukemia | — | P2 | BB · 71 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Azacitidine in Myeloproliferative Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/azacitidine-myeloproliferative-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →